Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ACELYRIN, INC. - Common Stock
(NQ:
SLRN
)
2.270
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ACELYRIN, INC. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
January 02, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
December 11, 2024
Via
Benzinga
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
December 10, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Earnings Scheduled For November 13, 2024
↗
November 13, 2024
Via
Benzinga
Earnings Preview: Acelyrin
↗
November 12, 2024
Via
Benzinga
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
↗
August 13, 2024
SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
↗
May 15, 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
November 13, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
November 06, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
October 16, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
September 19, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
↗
March 28, 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
September 10, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
August 22, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
↗
August 20, 2024
Via
Benzinga
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
↗
August 14, 2024
Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab.
Via
Benzinga
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
↗
August 14, 2024
Via
Benzinga
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
August 06, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
July 08, 2024
Via
Benzinga
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
June 05, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
May 29, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
May 09, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Leadership Transition
May 09, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
April 29, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
March 28, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
↗
March 20, 2024
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half...
Via
Benzinga
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
March 20, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
